Biohaven Pharmaceutical Biohaven is engaged in the identification and development of clinical stage neuroscience compounds targeting the glutamatergic system. | Shandong Saito Biotechnology Shandong Saito Biotechnology (山东斋藤生物科技) is a company that is engaged in the research and development and production of steroid drug intermediates. | |||
Founding Date | Founding Date 1916 | Founding Date 2014 | Founding Date 2010 | Founding Date 1966 |
Type | Type Public | Type Subsidiary | Type Public | Type Subsidiary |
Tags | ||||
Locations | Locations Parkville, AU HQ King Of Prussia, US | Locations New Haven, US HQ | Locations Heze, CN HQ | Locations Pune, IN HQ Mumbai, IN Pune, IN |
Employees | Employees 32,6982% increase | Employees 4692% decrease | Employees 1,200 | Employees 4,8671% increase |
Valuation ($) | Valuation ($) 95.1 b | Valuation ($) N/A | Valuation ($) 642.4 m | Valuation ($) N/A |
Financial | ||||
Revenue (est.) | Revenue (est.) $14.7b (FY, 2024) | Revenue (est.) N/A | Revenue (est.) ¥1.2b (FY, 2023) | Revenue (est.) N/A |
Cost of goods | Cost of goods $6.2b (FY, 2024) | Cost of goods N/A | Cost of goods ¥994.2m (FY, 2023) | Cost of goods N/A |
Gross profit | Gross profit $8.6b (FY, 2024) | Gross profit N/A | Gross profit ¥271.8m (FY, 2023) | Gross profit N/A |
Net income | Net income $2.7b (FY, 2024) | Net income N/A | Net income ¥48.5m (FY, 2023) | Net income N/A |